Brent Sabatini
Fortuna: 536 071 $ al 31/07/2026
Fortuna: 536 071 $ al 31/07/2026
Brent Sabatini is Senior VP, Chief Financial & Accounting Officer at Vir Biotechnology, Inc. since 2026.
Formerly, Mr. Sabatini was Head-Finance at Capsida Biotherapeutics, Inc. from 2021 to 2023.
Education includes an MBA from Stephen M.
Ross School of Business and an undergraduate degree from The California State University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VIR BIOTECHNOLOGY, INC. 0,04 % | 01/06/2026 | 61.902 ( 0,04 % ) | 536 071 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Director Financiero/CFO | 03/08/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Corporate Officer/Principal | 01/02/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
The California State University
The California State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stephen M. Ross School of Business
Stephen M. Ross School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.